Fotios Loupakis
Fotios Loupakis
Istituto Oncologico Veneto, Padua ITALY
Verified email at
Cited by
Cited by
Liquid biopsy: monitoring cancer-genetics in the blood
E Crowley, F Di Nicolantonio, F Loupakis, A Bardelli
Nature reviews Clinical oncology 10 (8), 472-484, 2013
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
S Kopetz, A Grothey, R Yaeger, E Van Cutsem, J Desai, T Yoshino, ...
New England Journal of Medicine 381 (17), 1632-1643, 2019
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular…
C Cremolini, F Loupakis, C Antoniotti, C Lupi, E Sensi, S Lonardi, S Mezi, ...
The Lancet Oncology 16 (13), 1306-1315, 2015
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer
F Loupakis, C Cremolini, G Masi, S Lonardi, V Zagonel, L Salvatore, ...
New England Journal of Medicine 371 (17), 1609-1618, 2014
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
G Siravegna, B Mussolin, M Buscarino, G Corti, A Cassingena, ...
Nature medicine 21 (7), 795-801, 2015
KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
F Loupakis, A Ruzzo, C Cremolini, B Vincenzi, L Salvatore, D Santini, ...
British journal of cancer 101 (4), 715-721, 2009
Primary tumor location as a prognostic factor in metastatic colorectal cancer
F Loupakis, D Yang, L Yau, S Feng, C Cremolini, W Zhang, MKH Maus, ...
Journal of the National Cancer Institute 107 (3), dju427, 2015
PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer
F Loupakis, L Pollina, I Stasi, A Ruzzo, M Scartozzi, D Santini, G Masi, ...
J Clin Oncol 27 (16), 2622-2629, 2009
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy
A Ruzzo, F Graziano, F Loupakis, E Rulli, E Canestrari, D Santini, ...
Journal of clinical oncology 25 (10), 1247-1254, 2007
Quantitative evidence for early metastatic seeding in colorectal cancer
Z Hu, J Ding, Z Ma, R Sun, JA Seoane, J Scott Shaffer, CJ Suarez, ...
Nature genetics 51 (7), 1113-1122, 2019
Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E–mutant metastatic colorectal cancer: updated survival results and subgroup analyses from…
J Tabernero, A Grothey, E Van Cutsem, R Yaeger, H Wasan, T Yoshino, ...
Journal of Clinical Oncology 39 (4), 273, 2021
Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by…
G Masi, F Loupakis, L Pollina, E Vasile, S Cupini, S Ricci, IM Brunetti, ...
Annals of surgery 249 (3), 420-425, 2009
Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial
G Masi, F Loupakis, L Salvatore, L Fornaro, C Cremolini, S Cupini, ...
The lancet oncology 11 (9), 845-852, 2010
High Concordance of KRAS Status Between Primary Colorectal Tumors and Related Metastatic Sites: Implications for Clinical Practice
D Santini, F Loupakis, B Vincenzi, I Floriani, I Stasi, E Canestrari, E Rulli, ...
The oncologist 13 (12), 1270-1275, 2008
Assessment of a HER2 scoring system for colorectal cancer: results from a validation study
E Valtorta, C Martino, A Sartore-Bianchi, F Penaullt-Llorca, G Viale, ...
Modern Pathology 28 (11), 1481-1491, 2015
Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial
S Siena, M Di Bartolomeo, K Raghav, T Masuishi, F Loupakis, ...
The Lancet Oncology 22 (6), 779-789, 2021
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with…
C Cremolini, C Antoniotti, D Rossini, S Lonardi, F Loupakis, F Pietrantonio, ...
The Lancet Oncology 21 (4), 497-507, 2020
FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer
F Loupakis, C Cremolini, L Salvatore, G Masi, E Sensi, M Schirripa, ...
European journal of cancer 50 (1), 57-63, 2014
Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis
G Masi, E Vasile, F Loupakis, S Cupini, L Fornaro, G Baldi, L Salvatore, ...
Journal of the National Cancer Institute 103 (1), 21-30, 2011
Cancer dormancy: a model of early dissemination and late cancer recurrence
D Pez, MJ Labonte, P Bohanes, W Zhang, L Benhanim, Y Ning, ...
Clinical Cancer Research 18 (3), 645-653, 2012
The system can't perform the operation now. Try again later.
Articles 1–20